2RH Stock Overview
A specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
RedHill Biopharma Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.00 |
| 52 Week High | US$89.50 |
| 52 Week Low | US$5.65 |
| Beta | 3.67 |
| 1 Month Change | 0% |
| 3 Month Change | 12.28% |
| 1 Year Change | 18.52% |
| 3 Year Change | -99.69% |
| 5 Year Change | -99.85% |
| Change since IPO | -99.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2RH | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.6% | -0.6% |
| 1Y | 18.5% | -16.8% | 14.8% |
Return vs Industry: 2RH exceeded the German Pharmaceuticals industry which returned -24.1% over the past year.
Return vs Market: 2RH exceeded the German Market which returned 8.3% over the past year.
Price Volatility
| 2RH volatility | |
|---|---|
| 2RH Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 2RH's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 2RH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 53 | Dror Ben-Asher | www.redhillbio.com |
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn’s disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.
RedHill Biopharma Ltd. Fundamentals Summary
| 2RH fundamental statistics | |
|---|---|
| Market cap | €8.87m |
| Earnings (TTM) | -€28.66m |
| Revenue (TTM) | €3.52m |
2.5x
P/S Ratio-0.3x
P/E RatioIs 2RH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2RH income statement (TTM) | |
|---|---|
| Revenue | US$3.71m |
| Cost of Revenue | US$2.45m |
| Gross Profit | US$1.26m |
| Other Expenses | US$31.44m |
| Earnings | -US$30.17m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -23.56 |
| Gross Margin | 34.04% |
| Net Profit Margin | -813.97% |
| Debt/Equity Ratio | 0% |
How did 2RH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/11/16 02:15 |
| End of Day Share Price | 2024/08/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
RedHill Biopharma Ltd. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| null null | BTIG |
| Brandon Folkes | Cantor Fitzgerald & Co. |